Springworks Therapeutics, Inc. (SWTX)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research

Current Price

as of Mar 12, 2025

$50.88

P/E Ratio

N/A

Market Cap

$3.81B

Loading...
Description
Add to research

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.

Metrics
Add to research

Overview

  • HQStamford, CT
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerSWTX
  • Price$50.88-0.02%

Trading Information

  • Market cap$3.81B
  • Float93.80%
  • Average Daily Volume (1m)2,863,903
  • Average Daily Volume (3m)2,384,806
  • EPS-$3.48

Company

  • Revenue$191.59M
  • Rev growth (1yr)3,417.33%
  • Net income-$258.13M
  • Gross margin91.95%
  • EBITDA margin-143.36%
  • EBITDA-$274.66M
  • EV$2.38B
  • EV/Revenue12.41
  • P/EN/A
  • P/S19.69
  • P/B7.87
  • Debt/Equity1.64
Documents
Add to research
SEC Filings
8-K (2025-02-20)
8-K (2025-02-12)
8-K (2025-01-13)
8-K (2024-11-12)
8-K (2024-08-07)
8-K (2024-07-30)
8-K (2024-06-07)
8-K (2024-05-17)
8-K (2024-05-02)
8-K (2024-02-27)
8-K (2024-02-02)
8-K (2023-12-06)
8-K (2023-11-28)
8-K (2023-11-17)
8-K (2023-11-02)
8-K (2023-09-01)
8-K (2023-08-02)
8-K (2023-06-05)
8-K (2023-05-25)
8-K (2023-05-03)
8-K (2023-03-10)
8-K (2023-02-28)
10-Q (2024-11-12)
10-Q (2024-08-07)
10-Q (2024-05-02)
10-Q (2023-11-02)
10-Q (2023-08-02)
10-Q (2023-05-03)
10-K (2025-02-20)
10-K (2024-02-27)
10-K (2023-02-28)
Earnings Calls
Earnings Report 2024Q3
Earnings Report 2024Q2
Earnings Report 2024Q1
Factset Street Account
Springworks Therapeutics reports Q3 EPS ($1.27) vs FactSet ($1.33) [5 est, ($1.41)-(1.15)] ($23.91, 0.00) (2023-11-02T10:40:23Z)
SpringWorks Therapeutics presenting additional data from Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors at CTOS ($22.90, 0.00) (2023-11-01T10:37:21Z)
Springworks Therapeutics announces wholesale acquisition cost for a 30-day supply of OGSIVEO at $29K - 8-K ($20.77, 0.00) (2023-11-28T14:09:46Z)
SpringWorks Therapeutics announces positive topline results from the Phase 2B ReNeu trial of Mirdametinib in NF1-PN ($22.07, 0.00) (2023-11-16T11:35:15Z)
Follow-up: SpringWorks issues press release on FDA approval of Ogsiveo; conference call today at 8:00ET (yesterday post-close) ($20.77, 0.00) (2023-11-28T11:22:47Z)
FDA approves Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment ($20.77, 0.00) (2023-11-27T23:13:01Z)